

Glenzocimab

Cat. No.:	HY-P99644
CAS No.:	2101829-58-5
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke ^{[1][2]} .	
In Vitro	Glenzocimab (0-100000 ng/mL) inhibits GPVI-Fc binding to collagen immobilized on a microtitration plate with an IC ₅₀ of 1.37 µg/mL ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Glenzocimab (1-8 mg/kg; i.v.) inhibits collagen-induced platelet aggregation in cynomolgus monkeys ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Cynomolgus monkeys ^[2]
	Dosage:	1-8 mg/kg
	Administration:	I.v.
	Result:	Reversibly inhibited collagen-induced platelet aggregation, at 2 to 8 mg/kg doses, collagen-induced platelet aggregation measured 0.5 hour after the end of the administration was fully inhibited for all cynomolgus.

REFERENCES

[1]. Wichaiyo S, et al. Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. *Stroke*. 2022 Nov;53(11):3506-3513.

[2]. Lebozec K, et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks. *MAbs*. 2017 Aug/Sep;9(6):945-958.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA